% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • bobbifleiss bobbifleiss Sep 12, 2013 10:44 AM Flag

    The Bull Case For Galena Is...

    Expectations are ultra low. With a market cap of $200 million the stock is priced for NeuVax's failure. Yet, with a 78% reduction in recurrence and no approved drugs to prevent recurrence in low-intermediate levels of HER2, Galena has a great shot.

    Abstral is flying under-the-radar, has now launched and has zero expectations. If sales are even remotely decent, GALE will fly.

    Worst case scenario, Abstral flops and NeuVax fails, GALE is a $0.50 stock.

    Best Case = Abstral $100m and NeuVax has great preliminary data = GALE a $15 stock.

    The math is quite simple

    Sentiment: Buy

1.74+0.01(+0.58%)Oct 9 3:59 PMEDT